SCHEMBL20141887

SCHEMBL20141887

CCCCC(C)(C(=O)O)N1CCC1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
GNAI3 P08754 1/20 0.32
GNAO1 P09471 1/20 0.32
GNAI1 P63096 1/20 0.32
CA2 P00918 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP2D6 P10635 1/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30
HIF1A Q16665 1/20 0.30
AKR1B1 P15121 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2578522 0.86 GNAI3 (0.43) MEN1KMT2AALDH1A1MAPTGNAI3
SCHEMBL9698366 0.79 L3MBTL1 (0.40) L3MBTL1MEN1KMT2ATDP1ALDH1A1
SCHEMBL8537023 0.78 TSHR (0.35) TDP1ALDH1A1CYP2D6TSHRCYP2C19
SCHEMBL30607042 0.75 SLC6A2 (0.43) MEN1KMT2AALDH1A1
SCHEMBL20759437 0.72
SCHEMBL28614341 0.72 L3MBTL1 (0.32) L3MBTL1MEN1KMT2ATDP1ALDH1A1
SCHEMBL7525549 0.71 GNAI3 (0.33) GNAI3GNAO1GNAI1
SCHEMBL607576 0.71 FDPS (0.40) MEN1KMT2ATDP1ALDH1A1CA2
SCHEMBL21757146 0.71 CYP1A2 (0.30)
SCHEMBL607577 0.71 FDPS (0.40) MEN1KMT2ATDP1ALDH1A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538526-A1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS Bristol-Myers Squibb Company (US) 2019-09-18 EP disclosed
WO-2018089355-A1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-17 WO disclosed